The Transmembrane Mutation G380R in Fibroblast Growth Factor Receptor 3 Uncouples Ligand-Mediated Receptor Activation from Down-Regulation

REFERENCES

• Basilico, C., and Moscatelli, D.. 1992. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59:115–165
   PubMed Web of Science ®Google Scholar
• Bellus, G. A., McIntosh, I., Szabo, J., Aylsworth, A., Kaitila, I., and Francomano, C. A.. 1996. Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Ann. N. Y. Acad. Sci. 785:182–187
   PubMedGoogle Scholar
• Cancedda, R., Descalzi Cancedda, F., and Castagnola, P.. 1995. Chondrocyte differentiation. Int. Rev. Cytol. 159:265–358
   PubMed Web of Science ®Google Scholar
• Coffin, J. D., Florkiewicz, R. Z., Neumann, J., Mort-Hopkins, T., Dorn, G. W.II, Lightfoot, P., German, R., Howles, P. N., Kier, A., O'Toole, B. A. et al. 1995. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell 6:1861–1873
   PubMed Web of Science ®Google Scholar
• Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G., and Ornitz, D. M.. 1996. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet. 12:390–397
   PubMed Web of Science ®Google Scholar
• Delezoide, A. L., Lasselin-Benoist, C., Legeai-Mallet, L., Brice, P., Senee, V., Yayon, A., Munnich, A., Vekemans, M., and Bonaventure, J.. 1997. Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses. Hum. Mol. Genet. 6:1899–1906
   PubMedGoogle Scholar
• Deng, C., Wynshaw, B. A., Zhou, F., Kuo, A., and Leder, P.. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911–921
   PubMed Web of Science ®Google Scholar
• Givol, D., and Yayon, A.. 1992. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J. 6:3362–3369
   PubMed Web of Science ®Google Scholar
• Grigoriadis, A. E., Heersche, J. N., and Aubin, J. E.. 1988. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. J. Cell Biol. 106:2139–2151
   PubMed Web of Science ®Google Scholar
• Horton, W. A., Machado, M. A., Ellard, J., Campbell, D., Putnam, E. A., Aulthouse, A. L., Sun, X., and Sandell, L. J.. 1993. An experimental model of human chondrocyte differentiation. Prog. Clin. Biol. Res. 3838:533–540
   Google Scholar
• Jingushi, S., Scully, S. P., Joyce, M. E., Sugioka, Y., and Bolander, M. E.. 1995. Transforming growth factor-beta 1 and fibroblast growth factors in rat growth plate. J. Orthop. Res. 13:761–768
   PubMedGoogle Scholar
• Johnson, D. E., and Williams, L. T.. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60:1–41
   PubMed Web of Science ®Google Scholar
• Keegan, K., Meyer, S., and Hayman, M. J.. 1991. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6:2229–2236
   PubMedGoogle Scholar
• Leach, R. J., Sokol, C., and McMurtry, J. P.. 1997. Immunolocalization of basic fibroblast growth factor in porcine epiphyseal growth plate. Domest. Anim. Endocrinol. 14:129–132
   PubMedGoogle Scholar
• Li, Y., Mangasarian, K., Mansukhani, A., and Basilico, C.. 1997. Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 14:1397–1406
   PubMed Web of Science ®Google Scholar
• McConahey, P. J., and Dixon, F. J.. 1980. Radioiodination of proteins by the use of the chloramine-T method. Methods Enzymol. 70:210–213
   PubMedGoogle Scholar
• McDougall, S., Fu, Y. H., Lowe, G. N., Williams, A., Polendo, R., Benya, P. D., Iida-Klein, A., Fang, M. A., and Hahn, T. J.. 1996. Surface adhesion-mediated regulation of chondrocyte-specific gene expression in the nontransformed RCJ 3.1C5.18 rat chondrocyte cell line. J. Bone Miner. Res. 11:1130–1138
   PubMedGoogle Scholar
• Naski, M. C., Wang, Q., Xu, J., and Ornitz, D. M.. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 13:233–237
   PubMed Web of Science ®Google Scholar
• Nilsson, A., Ohlsson, C., Isaksson, O. G., Lindahl, A., and Isgaard, J.. 1994. Hormonal regulation of longitudinal bone growth. Eur. J. Clin. Nutr. 48 (Suppl. 1):S150–158
   PubMedGoogle Scholar
• Peters, K., Ornitz, D., Werner, S., and Williams, L.. 1993. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol. 155:423–430
   PubMed Web of Science ®Google Scholar
• Peters, K. G., Werner, S., Chen, G., and Williams, L. T.. 1992. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development 114:233–243
   PubMed Web of Science ®Google Scholar
• Ponseti, I. V.. 1970. Skeletal growth in achondroplasia. J. Bone Jt. Surg. Am. Vol. 52:701–716
   PubMedGoogle Scholar
• Ponseti, I. V.. 1988. Bone formation in achondroplasia. Basic Life Sci. 48:109–122
   PubMedGoogle Scholar
• Raffioni, S., Zhu, Y. Z., Bradshaw, R. A., and Thompson, L. M.. 1998. Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation. J. Biol. Chem. 273:35250–35259
   PubMedGoogle Scholar
• Robertson, S. C., Meyer, A. N., Hart, K. C., Galvin, B. D., Webster, M. K., and Donoghue, D. J.. 1998. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc. Natl. Acad. Sci. USA 95:4567–4572
   PubMedGoogle Scholar
• Rossant, J., Ciruna, B., and Partanen, J.. 1997. FGF signaling in mouse gastrulation and anteroposterior patterning. Cold Spring Harbor Symp. Quant. Biol. 62:127–133
   PubMedGoogle Scholar
• Rousseau, F., Bonaventure, J., Legeai, M. L., Pelet, A., Rozet, J. M., Maroteaux, P., Le, M. M., and Munnich, A.. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252–254
   PubMed Web of Science ®Google Scholar
• Rousseau, F., el Ghouzzi, V., Delezoide, A. L., Legeai-Mallet, L., Le Merrer, M., Munnich, A., and Bonaventure, J.. 1996. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum. Mol. Genet. 5:509–512
   PubMedGoogle Scholar
• Segev, O., Chumakov I., Nevo Z., Givol D., Madar-Shapiro L., Sheinin Y., Weinreb M., and Yayon A.. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3G380R transgenic mice. Hum. Mol. Genet., in press.
   Google Scholar
• Shiang, R., Thompson, L. M., Zhu, Y. Z., Church, D. M., Fielder, T. J., Bocian, M., Winokur, S. T., and Wasmuth, J. J.. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335–342
   PubMed Web of Science ®Google Scholar
• Sorkin, A., Helin, K., Waters, C. M., Carpenter, G., and Beguinot, L.. 1992. Multiple autophosphorylation sites of the epidermal growth factor receptor are essential for receptor kinase activity and internalization. Contrasting significance of tyrosine 992 in the native and truncated receptors. J. Biol. Chem. 267:8672–8678
   PubMed Web of Science ®Google Scholar
• Sorkin, A., Waters, C., Overholser, K. A., and Carpenter, G.. 1991. Multiple autophosphorylation site mutations of the epidermal growth factor receptor. Analysis of kinase activity and endocytosis. J. Biol. Chem. 266:8355–8362
   PubMedGoogle Scholar
• Sorokin, A., Mohammadi, M., Huang, J., and Schlessinger, J.. 1994. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. J. Biol. Chem. 269:17056–17061
   PubMed Web of Science ®Google Scholar
• Tavormina, P. L., Shiang, R., Thompson, L. M., Zhu, Y. Z., Wilkin, D. J., Lachman, R. S., Wilcox, W. R., Rimoin, D. L., Cohn, D. H., and Wasmuth, J. J.. 1995. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet. 9:321–328
   PubMed Web of Science ®Google Scholar
• Thompson, L. M., Raffioni, S., Wasmuth, J. J., and Bradshaw, R. A.. 1997. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells. Mol. Cell. Biol. 17:4169–4177
   PubMedGoogle Scholar
• Ullrich, A., and Schlessinger, J.. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212
   PubMed Web of Science ®Google Scholar
• Webster, M. K., D'Avis, P. Y., Robertson, S. C., and Donoghue, D. J.. 1996. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16:4081–4087
   PubMed Web of Science ®Google Scholar
• Webster, M. K., and Donoghue, D. J.. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15:520–527
   PubMed Web of Science ®Google Scholar
• Webster, M. K., and Donoghue, D. J.. 1997. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 13:178–182
   PubMed Web of Science ®Google Scholar
• Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., and Greene, M. I.. 1989. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230–231
   PubMed Web of Science ®Google Scholar
• Wilkie, A. O., Morriss, K. G., Jones, E. Y., and Heath, J. K.. 1995. Functions of fibroblast growth factors and their receptors. Curr. Biol. 5:500–507
   PubMedGoogle Scholar
• Wuechner, C., Nordqvist, A. C., Winterpacht, A., Zabel, B., and Schalling, M.. 1996. Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse. Int. J. Dev. Biol. 40:1185–1188
   PubMedGoogle Scholar